BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36268974)

  • 1. Clinical Outcomes and Treatment Strategies in Patients With Non-Carbapenemase-producing Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacterales Infections.
    Debnath A; Pillinger KE; Martin AJ; Dobrzynski D; Cameron A; Shulder S
    Ann Pharmacother; 2023 Jul; 57(7):803-812. PubMed ID: 36268974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant
    Cancelli F; Oliva A; De Angelis M; Mascellino MT; Mastroianni CM; Vullo V
    Biomed Res Int; 2018; 2018():2785696. PubMed ID: 30581848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
    Tamma PD; Goodman KE; Harris AD; Tekle T; Roberts A; Taiwo A; Simner PJ
    Clin Infect Dis; 2017 Feb; 64(3):257-264. PubMed ID: 28013264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia.
    Hovan MR; Narayanan N; Cedarbaum V; Bhowmick T; Kirn TJ
    Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115505. PubMed ID: 34399381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study.
    Hassoun-Kheir N; Hussein K; Karram M; Saffuri M; Badaan S; Peleg S; de Kraker MEA; Aboelhega W; Warman S; Alon T; Eluk O; Geffen Y; Paul M
    Clin Microbiol Infect; 2023 May; 29(5):629-634. PubMed ID: 36641053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment and Outcomes of Infections Caused by Diverse Carbapenemase-Producing Carbapenem-Resistant
    Lim FK; Liew YX; Cai Y; Lee W; Teo JQM; Lay WQ; Chung J; Kwa ALH
    Front Cell Infect Microbiol; 2020; 10():579462. PubMed ID: 33178629
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical characteristics and outcomes of carbapenem-resistant Enterobacterales bacteremia in pediatric patients.
    Liu YC; Lu CY; Yen TY; Chang LY; Chen JM; Lee PI; Huang LM
    J Microbiol Immunol Infect; 2023 Feb; 56(1):84-92. PubMed ID: 36376217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Insights Into the Mechanism of Carbapenem Resistance Dissemination in Enterobacterales From a Tertiary Public Heath Setting in South Asia.
    Farzana R; Jones LS; Rahman MA; Sands K; van Tonder AJ; Portal E; Criollo JM; Parkhill J; Guest MF; Watkins WJ; Pervin M; Boostrom I; Hassan B; Mathias J; Kalam MA; Walsh TR
    Clin Infect Dis; 2023 Jan; 76(1):119-133. PubMed ID: 35412593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant
    Saito S; Hayakawa K; Tsuzuki S; Ishikane M; Nagashima M; Mezaki K; Sugiki Y; Tajima T; Matsunaga N; Ide S; Kinoshita N; Kusama Y; Fujitomo Y; Nakamoto T; Toda Y; Kaku M; Kodama EN; Ohmagari N
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33257451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular characteristics and risk factors for patients acquiring carbapenemase-producing and non-carbapenemase-producing carbapenem-nonsusceptible-Enterobacterales bacteremia.
    Wu AY; Chang H; Wang NY; Sun FJ; Liu CP
    J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1229-1238. PubMed ID: 34824020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study.
    Stewardson AJ; Marimuthu K; Sengupta S; Allignol A; El-Bouseary M; Carvalho MJ; Hassan B; Delgado-Ramirez MA; Arora A; Bagga R; Owusu-Ofori AK; Ovosi JO; Aliyu S; Saad H; Kanj SS; Khanal B; Bhattarai B; Saha SK; Uddin J; Barman P; Sharma L; El-Banna T; Zahra R; Saleemi MA; Kaur A; Iregbu K; Uwaezuoke NS; Abi Hanna P; Feghali R; Correa AL; Munera MI; Le TAT; Tran TTN; Phukan C; Phukan C; Valderrama-Beltrán SL; Alvarez-Moreno C; Walsh TR; Harbarth S
    Lancet Infect Dis; 2019 Jun; 19(6):601-610. PubMed ID: 31047852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
    Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
    Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Factors for Carbapenem-Resistant
    Rebold N; Lagnf AM; Alosaimy S; Holger DJ; Witucki P; Mannino A; Dierker M; Lucas K; Kunz Coyne AJ; El Ghali A; Caniff KE; Veve MP; Rybak MJ
    Microbiol Spectr; 2023 Feb; 11(1):e0264722. PubMed ID: 36622246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological Characteristics of Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae Colonization.
    Jeong IS; Song JY
    Asian Nurs Res (Korean Soc Nurs Sci); 2022 Aug; 16(3):134-139. PubMed ID: 35605957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
    Pang F; Jia XQ; Zhao QG; Zhang Y
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018.
    Perovic O; Ismail H; Quan V; Bamford C; Nana T; Chibabhai V; Bhola P; Ramjathan P; Swe Swe-Han K; Wadula J; Whitelaw A; Smith M; Mbelle N; Singh-Moodley A;
    Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1287-1294. PubMed ID: 32124106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
    Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections.
    Wang Q; Zhang Y; Yao X; Xian H; Liu Y; Li H; Chen H; Wang X; Wang R; Zhao C; Cao B; Wang H
    Eur J Clin Microbiol Infect Dis; 2016 Oct; 35(10):1679-89. PubMed ID: 27401905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Likelihood of Developing a Carbapenem-Resistant
    Tamma PD; Kazmi A; Bergman Y; Goodman KE; Ekunseitan E; Amoah J; Simner PJ
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenem-resistant
    Ruvinsky S; Voto C; Roel M; Deschutter V; Ferraro D; Aquino N; Reijtman V; Galvan ME; Motto E; García M; Sarkis C; Bologna R
    Front Public Health; 2022; 10():983174. PubMed ID: 36091556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.